# The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)

> **NCT05624827** · NA · UNKNOWN · sponsor: **University Medical Centre Maribor** · enrollment: 100 (estimated)

## Conditions studied

- Cervical Intraepithelial Neoplasia Grade 2
- DNA Methylation

## Interventions

- **DIAGNOSTIC_TEST:** Testing DNA methylation test for predicting prognosis of untreated CIN 2

## Key facts

- **NCT ID:** NCT05624827
- **Lead sponsor:** University Medical Centre Maribor
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624827, "The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05624827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*